5 Key Takeaways
-
1
The phase 1 JADE study compared OLN324 to faricimab in treating age-related macular degeneration and diabetic macular edema.
-
2
OLN324 demonstrated better retinal drying and a higher percentage of DME resolution compared to faricimab at week 12.
-
3
In AMD, OLN324 showed a gain of 2.2 letters and more significant flattening of pigment epithelial detachments than faricimab.
-
4
OLN324's small format (41 kDa) allows for high binding affinity and molarity, distinguishing it from faricimab.
-
5
No intraocular inflammation, vascular occlusions, or endophthalmitis were reported in OLN324 patients during the study.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
